AnaptysBio, Inc. (NASDAQ:ANAB) Receives Average Rating of "Moderate Buy" from Analysts

AnaptysBio, Inc. (NASDAQ:ANAB - Get Free Report) has earned a consensus rating of "Moderate Buy" from the eleven brokerages that are covering the company, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, three have issued a hold recommendation, six have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month price target among brokers that have covered the stock in the last year is $48.75.

A number of research firms recently issued reports on ANAB. HC Wainwright raised their price target on AnaptysBio from $38.00 to $59.00 and gave the stock a "buy" rating in a research note on Tuesday, September 30th. Weiss Ratings restated a "sell (d-)" rating on shares of AnaptysBio in a research note on Saturday, September 27th. UBS Group restated a "neutral" rating and set a $20.00 price target (up previously from $18.00) on shares of AnaptysBio in a research note on Tuesday, August 12th. JPMorgan Chase & Co. raised their price target on AnaptysBio from $42.00 to $80.00 and gave the stock an "overweight" rating in a research note on Thursday, July 24th. Finally, Wedbush reiterated an "outperform" rating and issued a $45.00 target price on shares of AnaptysBio in a research note on Tuesday, September 30th.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Rhumbline Advisers grew its stake in shares of AnaptysBio by 2.7% in the 1st quarter. Rhumbline Advisers now owns 30,903 shares of the biotechnology company's stock valued at $574,000 after purchasing an additional 826 shares during the last quarter. US Bancorp DE grew its stake in shares of AnaptysBio by 126.5% in the 1st quarter. US Bancorp DE now owns 1,753 shares of the biotechnology company's stock valued at $33,000 after purchasing an additional 979 shares during the last quarter. Corton Capital Inc. grew its stake in shares of AnaptysBio by 12.2% in the 2nd quarter. Corton Capital Inc. now owns 12,004 shares of the biotechnology company's stock valued at $266,000 after purchasing an additional 1,305 shares during the last quarter. California State Teachers Retirement System grew its stake in shares of AnaptysBio by 10.3% in the 4th quarter. California State Teachers Retirement System now owns 14,590 shares of the biotechnology company's stock valued at $193,000 after purchasing an additional 1,359 shares during the last quarter. Finally, Tower Research Capital LLC TRC grew its stake in shares of AnaptysBio by 175.0% in the 2nd quarter. Tower Research Capital LLC TRC now owns 2,164 shares of the biotechnology company's stock valued at $48,000 after purchasing an additional 1,377 shares during the last quarter.

AnaptysBio Stock Down 1.3%

NASDAQ:ANAB opened at $29.87 on Wednesday. The stock's 50 day moving average price is $22.57 and its 200 day moving average price is $22.05. The company has a market capitalization of $836.36 million, a PE ratio of -6.67 and a beta of -0.18. AnaptysBio has a 52-week low of $12.21 and a 52-week high of $36.54.

AnaptysBio (NASDAQ:ANAB - Get Free Report) last released its quarterly earnings results on Wednesday, August 6th. The biotechnology company reported ($1.34) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.50) by $0.16. The firm had revenue of $22.26 million for the quarter, compared to the consensus estimate of $11.55 million. AnaptysBio had a negative return on equity of 366.98% and a negative net margin of 107.66%. As a group, sell-side analysts anticipate that AnaptysBio will post -6.08 EPS for the current fiscal year.

About AnaptysBio

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.